Injection drug use has played an important role in parenteral transmission of HIV, hepati tis B virus (HBV), and hepatitis C virus (HCV). Several studies have described high preva lence of antibodies to HCV (anti-HCV) and hepatitis B core antigen (anti-HBc) among in jection drug users (IDUs) in the United States and other countries [1] [2] [3] and have measured coinfection rates of HIV, HBV, and HCV. 1, 2, [4] [5] [6] Sera were originally collected from 1993 to 1994 for the Centers for Disease Control and Prevention (CDC) national HIV sero prevalence surveys to measure the prevalence of anti-HBc, anti-HCV, and HIV among IDUs entering treatment in 6 US cities: Newark, NJ; Baltimore, Md; Detroit, Mich; Denver, Colo; San Francisco, Calif; and Seattle, Wash. By using standardized methods 7, 8 for measuring prevalence in these 6 cities, we added agespecific and geographic data to the existing body of information about the national HBV, HCV, and HIV endemic among IDUs.
METHODS
We used remnant sera collected from per sons entering treatment for use of illicit drugs other than alcohol during the CDC's 1993 to 1994 national HIV seroprevalence surveys of IDUs. These serum samples were tested for HIV antibodies after all personal identifiers (client's name, medical record number) had been permanently removed. 7 In consultation with state and local health departments, sites (primarily methadone maintenance programs) were selected on the basis of geographic rep resentation and population characteristics. Limited information on demographic charac teristics and drug use was abstracted from client files at each survey site. Routine HIV-1 antibody testing was done with an enzyme immunoassay licensed by the Objectives. virus (HCV) infection among injection drug users (IDUs) admitted to drug treatment programs in 6 US cities.
Methods. Remnant sera collected from persons entering treatment with a history of illicit drug injec
Results. This study measured age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C tion were tested for antibodies to HIV, hepatitis C (anti-HCV), and hepatitis B core antigen (anti-HBc).
Conclusions
Prevalence of anti-HBc and anti-HCV increased with age and reached 80% to 100% among older IDUs in all 6 cities. Although overall age-specific HIV prevalence was lower than anti-HCV or antiHBc, this prevalence was greater in the Northeast than in the Midwest and West.
. The need continues for effective primary prevention programs among IDUs specifically tar geting young persons who have recently started to inject drugs.
US Food and Drug Administration. Sera that were repeatedly reactive were confirmed by Western blot. Western blot band patterns were interpreted according to the recommen dations of the Association of Public Health Laboratories and the CDC. 9 After HIV testing, stored sera were tested for anti-HBc and anti-HCV at the Hepatitis Reference Laboratory, CDC. Anti-HBc testing was performed with a radioimmunoassay (CORAB; Abbott Laboratories, Inc, Abbott Park, North Chicago, Ill), and anti-HCV testing was done with an enzyme immunoassay (HCV EIA 2.0; Abbott Laboratories, Inc); the first 100 specimens that were repeatedly re active were tested with a supplemental assay (HCV MATRIX; Abbott Laboratories, Inc). Because 99 of the 100 repeatedly reactive specimens were also positive with the supple mental assay, the remainder of the specimens was considered anti-HCV positive if repeat edly reactive by enzyme immunoassay.
Prevalence was calculated by city and de mographic group; age was categorized into 5 year groups.
RESULTS
Demographic characteristics and preva lence of HIV, anti-HBc, and anti-HCV among the 1717 persons tested in the 6 cities are shown in Table 1 . Overall, 35% of the per sons tested were female, 37% were younger than 35, and 43% were White. A higher pro portion of the sampled IDUs were younger than 35 years in San Francisco (49%), New ark (40%), and Seattle (45%) than in the other cities. HIV seroprevalence was 28% to 29% in cities in the Northeast, compared with 3% to 5% in cities in the Midwest and West. However, the prevalence of anti-HBc (50%-81%) and anti-HCV (66%-93%) was high in all geographic regions.
The prevalence of anti-HBc and anti-HCV increased with age and reached 80% to 100% among older IDUs in all 6 cities ( Figure  1) . Prevalence of anti-HCV was consistently higher than that of anti-HBc across all age groups in the 6 cities. In contrast, HIV sero prevalence also increased with age but peaked at 30% to 40% in Newark and Baltimore and at approximately 5% in the other 4 cities.
χ Seroprevalence of HIV did not differ signif icantly by sex or race/ethnicity in the 6 cities (data not shown). Anti-HBc prevalence was significantly higher in non-White than in White persons in Baltimore (85% vs 63%: 2 = 12.8, P < .01), Seattle (74% vs 55%: χ 2 = 9.5, P < .01), and San Francisco (71% vs 40%: χ 2 = 31.0, P < .01). Anti-HBc seropreva- Note. HBV = hepatitis B virus.
lence was higher in men than in women in DISCUSSION duration of injection drug use may lead to San Francisco (56% vs 39%: χ 2 = 9.1, P < more sharing of needles and other equipment .01). Anti-HCV seroprevalence differed signifOur finding that HIV, anti-HBc, and antisuch as cotton and cookers, resulting in a icantly between non-White and White per-HCV prevalence increased with age is consisgreater likelihood of transmission. 10, 11 sons in San Francisco (87% vs 60%: χ 2 = tent with the results of previous studies and Among IDUs entering treatment in 6 cities 28.3, P < .01) and between men and women suggests that the prevalence of infection is asin the United States during 1993 to 1994, in Baltimore (96% vs 88%: χ 2 = 6.1, P = .01). sociated with duration of drug use. 1, 10 Longer the greater HIV seroprevalence in the North- Note. Anti-HBc = antibody to hepatitis B core antigen; anti-HCV = antibody to hepatitis C virus.
east compared with that in the Midwest and West has been observed in other studies. 7, 8 In contrast, HBV and HCV prevalence rates were high in all 6 cities. The higher overall prevalence of HBV and HCV than of HIV in IDUs in all 6 cities was likely related to the size of the reservoirs of these viruses in these communities. Geo graphic differences in HIV prevalence among IDUs in the United States have remained re markably consistent since at least the late 1980s, 8 an observation that has not been ex plained. One hypothesis is that higher HIV prevalence is observed in regions with higher population densities; larger social networks in these areas could increase risk for contact with a person who is HIV infected.
12
Our study population was limited to a se lected group of IDUs who were entering drug treatment programs in 6 US cities. Therefore, the observed seroprevalences of HIV, HBV, and HCV are not generalizable to all IDUs in these 6 cities. IDUs in treatment programs tend to be older than those not in treatment programs because programs usually admit only clients with well-established drug habits; therefore, these seroprevalence rates may be different from those among IDUs in general. However, the observed geographic differ ences were consistent with those observed in other studies. 1, 6, 13 Given the high prevalence of both HBV and HCV among IDUs, effective primary pre vention programs are needed because the likelihood that an uninfected novice IDU will come in contact with an infected IDU is great. Such programs should offer hepatitis B vacci nation, provide treatment to stop the use of illicit drugs, and promote the use of sterile needles and the nonsharing of equipment used to prepare and inject drugs (cotton, cookers, and water) for those who are unable to discontinue injection drug use. 14 
